Prestige Consumer Healthcare (NYSE:PBH) Raised to “Hold” at Zacks Research

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Several other research analysts have also issued reports on the stock. Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price for the company in a report on Wednesday, September 24th. Oppenheimer cut their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 21st. Jefferies Financial Group decreased their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research note on Monday, October 27th. Finally, Wall Street Zen lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and an average price target of $85.33.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH traded up $0.59 during trading hours on Monday, hitting $61.17. 108,303 shares of the company’s stock were exchanged, compared to its average volume of 416,596. Prestige Consumer Healthcare has a 1-year low of $59.18 and a 1-year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of 14.35, a PEG ratio of 1.93 and a beta of 0.41. The company’s 50-day moving average price is $62.71 and its 200-day moving average price is $72.86.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. The firm had revenue of $274.11 million for the quarter, compared to the consensus estimate of $257.14 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The business’s revenue was down 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.09 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, sell-side analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. UMB Bank n.a. increased its position in Prestige Consumer Healthcare by 81.8% during the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after purchasing an additional 144 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Prestige Consumer Healthcare by 312.5% during the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after buying an additional 250 shares in the last quarter. Maseco LLP bought a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at $27,000. First Horizon Corp acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter valued at $32,000. Finally, Hantz Financial Services Inc. grew its position in Prestige Consumer Healthcare by 373.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock worth $43,000 after acquiring an additional 538 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.